트랜스펙션 시약 및 장비 시장 보고서 : 제품별, 기술별, 용도별, 최종사용자별, 지역별(2026-2034년)

The global transfection reagents and equipment market size reached USD 1,104.4 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 1,904.2 Million by 2034, exhibiting a growth rate (CAGR) of 6.24% during 2026-2034.

Transfection reagents and equipment help modulate gene expression in eukaryotic cells in vitro and in vivo. They allow researchers to generate stable cell lines and introduce deoxyribonucleic acid (DNA) plasmids possessing gene inserts for expression and small interfering RNA (siRNA). They are currently being used as viable analytical tools for protein synthesis, cell growth and development, and facilitating the study of genetic functions. Besides this, as they provide cost-effective and rapid production of recombinant human therapeutic proteins in sufficient quantities, transfection reagents and equipment are also gaining traction in producing r-proteins, antibodies, and viral vectors for vaccines.

Transfection Reagents and Equipment Market Trends:

Due to the outbreak of coronavirus disease (COVID-19) globally, governing agencies of numerous countries are focusing on accelerating the vaccination drive. However, due to the emergence of new variants, the protection and immunity that these vaccines provide are short-lived. As a result, there is a rise in the need of transfection reagents and equipment to develop innovative strategies or alternatively repurpose existing treatments to fight against virus infection. Apart from this, rapid detection of new cancer variants, coupled with the escalating demand for precision medicine and high-quality oncology care, are driving the adoption of transfection reagents and equipment in cancer research and drug development. Moreover, the emerging use of gene therapies to treat rare diseases caused by genetic problems is impelling the market growth. Furthermore, due to the growing number of fatal road accidents across the globe, there is a significant rise in the demand for tissue engineering to develop functional substitutes for damaged tissues. This, in turn, is propelling the market growth. Besides this, recent advancements in transfection technologies, along with increasing investments in pharmaceutical and biotechnology sectors, are anticipated to drive the market.

Key Market Segmentation:

Breakup by Product:

• Reagents
• Equipment

Breakup by Technology:

• Biochemical Based Transfection
• Physical Transfection
• Viral-Vector Based Transfection

Breakup by Application:

• Biomedical Research
• Protein Production
• Therapeutic Delivery

Breakup by End User:

• Pharmaceutical and Biotechnology Companies
• Academics and Research Institutes

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The report provides a comprehensive analysis of the competitive landscape in the global transfection reagents and equipment market with detailed profiles of all major companies, including:

• Bio-Rad Laboratories, Inc
• Lonza Group AG
• MaxCyte
• Merck Life Science
• OriGene Technologies, Inc.
• Promega Corporation
• Qiagen N.V.
• Revvity, Inc.
• Sartorius AG
• SBS Genetech
• Takara Bio Inc
• Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

• 1.What was the size of the global transfection reagents and equipment market in 2025?
• 2.What is the expected growth rate of the global transfection reagents and equipment market during 2026-2034?
• 3.What are the key factors driving the global transfection reagents and equipment market?
• 4.What has been the impact of COVID-19 on the global transfection reagents and equipment market?
• 5.What is the breakup of the global transfection reagents and equipment market based on the product?
• 6.What is the breakup of the global transfection reagents and equipment market based on the technology?
• 7.What is the breakup of the global transfection reagents and equipment market based on the application?
• 8.What is the breakup of the global transfection reagents and equipment market based on the end user?
• 9.What are the key regions in the global transfection reagents and equipment market?
• 10.Who are the key players/companies in the global transfection reagents and equipment market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Transfection Reagents and Equipment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Reagents
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Equipment
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Technology

• 7.1 Biochemical Based Transfection
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Physical Transfection
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Viral-Vector Based Transfection
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Application

• 8.1 Biomedical Research
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Protein Production
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Therapeutic Delivery
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by End User

• 9.1 Pharmaceutical and Biotechnology Companies
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Academics and Research Institutes
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Bio-Rad Laboratories, Inc
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Lonza Group AG
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 MaxCyte
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
  • 15.3.4 Merck Life Science
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 OriGene Technologies, Inc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Promega Corporation
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Qiagen N.V.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Revvity, Inc.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Sartorius AG
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 SBS Genetech
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Takara Bio Inc
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis
  • 15.3.12 Thermo Fisher Scientific Inc.
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis